Target Nutra

The World-Wide Trial

Provisional: The scheme below may alter a little but applicants are invited to register and will be notified when the trial is to start.

World-Wide Trial of HF3

The 'Hopeful Trials' have been running in Britain since January 2017. This followed a year of research into formulation techniques which give relatively commonplace substances greatly increased antiviral potency. Some preliminary results can be seen on the Trials page.

Entry to the British trial was very restricted, but this new trial is open to anyone, anywhere. Previously, participants were provided with material free of charge, but this is not feasible for this global trial. A charge of US$20 must be paid for each consignment. However, if all goes to plan, just over half will have their money refunded; see below.

How to join the trial

Click on this register link and complete registration. When the trial is to start, you will be emailed and asked to pay US$20 via Paypal.

Once this stage is completed, you will be assigned one of the preparations (in rotation) and a logfile will be created to enable you to make reports. A bottle containing HF3 will be posted to you marked 'herbal remedy' (for Customs notification). Directions for its use will be included and these are also updated on this website.

Trial specification

Three preparations will be compared, HF3A, HF3B and HF3C:

  1. A modified version of HF2. This is an advanced formulation using Melissa officinalis (Lemon balm) as its active ingredient;

  2. A second variant of HF2, perhaps an improvement;

  3. A 'placebo' which will have little or no effect.

The object of the trial is to discover which of the two variants of HF2 is the most effective, and validate the results (including the existing results) with a control group.

No reports, no refund

Whether your reports are good or bad is completely irrelevant. Both positive and negative appraisals of the test preparation are equally welcome. Just be as accurate as you can.

Refunds will be issued according to the following scheme:

  1. Everyone receiving the placebo who makes a few reports will be refunded;

  2. Participants who make the most reports will be refunded, until 51% of participants is reached.

This refunding scheme favours firstly, those who receive the placebo and secondly, those who have the most frequent outbreaks and make reports.

If active HF3 is sent but there are not enough reports, the payment will be regarded as a purchase. If a member of the placebo group fails to make reports, their payment will be classed as a donation. The control group is as important as the other groups, because it validates the other reports. The money retained will offset the costs of materials and international postage.

Applicants should be aware of the following. Because HSV infections come and go and are highly variable (requiring longer trials), and because participants may be continuously enrolled over a period, it could be two years before some refunds are processed. Participants in the placebo group will likely receive refunds much sooner. Also, circumstances could arise, such as death or the Paypal account being shut down, which make it impossible to issue outstanding refunds. Best efforts will be made to conform to the trial scheme but some eventualities are unforeseen and unavoidable.

Additional comments

Five preparations have been tested in Britain in a comparative trial; there was no placebo. The problem is, all of them have been reported effective! If at least one had been useless, as was expected, it would have served as a reference point, but that did not happen. They are effective in different ways and to different degrees, but none can be regarded as a failure.

An alternative explanation for the consistently positive results is that all five preparations are equally useless. Given the many positive comments which have been made (in addition to the statistics), this is very unlikely. However the possibility demands that a control group be included in these new trials.

Please see the bottom of the Trials page for a Disclaimer etc.

Simon Sheppard
September 2019